Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcyte PK/PD Study in Breast Cancer
NCT03376503Phase 1Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoint: Area under the curve from time 0 to the last time point at Day 14. Started May 2016; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03376503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376503.